Todd Sone - 10 Jun 2021 Form 4 Insider Report for Ayala Pharmaceuticals, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 10 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Jun 2021, 16:58:14 UTC
Source filing: View source filing
Reporting owner signature: /s/ Roni Mamluk, Ph.D., Attorney-in-Fact for Todd Sone

Key filing fact

Todd Sone filed Form 4 for Ayala Pharmaceuticals, Inc. on 14 Jun 2021.

Key facts

This page summarizes Todd Sone's Form 4 filing for Ayala Pharmaceuticals, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Jun 2021, 16:58.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AYLA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +6,250
Change %
Price: $0.000000
Shares after: 6,250
Date: 10 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,250
Exercise price: $10.35
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option vests and becomes exercisable on the earlier of (i) June 10, 2022 or (ii) one day prior to the Company's 2022 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.

SEC remarks

Exhibit List: Exhibit 24 - Power of Attorney